ADAM17 and Parkinson disease: Many reports revealed that the enzyme activity of ADAM17 and ADAM10 decreased in AD which shares similar pathological mechanism with PD pathogenesis [33–35] and could cause a decline of sLAG3 in PD patients’ CSF.